Old Web
English
Sign In
Acemap
>
authorDetail
>
Fabrizio Febo
Fabrizio Febo
Medicine
Liraglutide
Lixisenatide
Semaglutide
Empagliflozin
3
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-World Setting.
2020
Clinical Therapeutics
Giulia Di Dalmazi
Sara Coluzzi
Maria Pompea Antonia Baldassarre
Sofia Elena Sorbo
Stefania Dell’Aquila
Fabrizio Febo
Federica Ginestra
Giusi Graziano
Maria Chiara Rossi
Agostino Consoli
Gloria Formoso
Show All
Source
Cite
Save
Citations (3)
A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
2018
Expert Opinion on Drug Safety
Agostino Consoli
Gloria Formoso
Maria Pompea Antonia Baldassarre
Fabrizio Febo
Show All
Source
Cite
Save
Citations (22)
Trattamento farmacologico del diabete mellito di tipo 2 e rischio cardiovascolare: cosa è possibile capire dai trial?
2016
Giornale italiano di cardiologia
Agostino Consoli
Fabrizio Febo
Show All
Source
Cite
Save
Citations (0)
1